Loading clinical trials...
Loading clinical trials...
The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Collaborators
NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more
NCT07098364 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and more
NCT06550141 · Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more
NCT06287398 · DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, and more
NCT04542824 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, and more
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions